Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.53 Analyst target: $7.00 Upside: 1220.75%
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. The company is headquartered in Los Angeles, California.
See the full interactive analysis & chart →Informational only — not investment advice.